株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

麻酔薬の世界市場:考察、市場機会の分析、市場シェア、予測

Global Anesthesia Drug Market Research Report Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 566329
出版日 ページ情報 英文 190 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=108.49円で換算しております。
麻酔薬の世界市場:考察、市場機会の分析、市場シェア、予測 Global Anesthesia Drug Market Research Report Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023
出版日: 2017年08月22日 ページ情報: 英文 190 Pages
概要

当レポートでは、麻酔薬の世界市場について調査し、市場・産業の概要、種類・麻酔方法・製品・地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因および市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 市場概要

  • 麻酔薬の世界市場:発展と変遷
  • 市場の定義と範囲
  • 産業構造
  • 市場分析
  • 予測分析
  • 戦略分析
    • 投資 vs 導入モデル
    • 全方位的産業分析
    • ファイブフォース分析
    • シーソー分析
    • ギャップ分析
    • 特許分析
    • 価格分析
    • コンシューマー分析・主な購買基準
  • 競合分析
    • 主要戦略とその分析
    • 市場シェアおよび主要企業の分析
  • 戦略提言
    • 地域別の投資機会
    • 新用途の市場機会
    • 最速成長市場の投資機会

第3章 市場の決定要因

  • 促進要因
  • 阻害要因
  • 市場機会
  • 市欧課題

第4章 市場区分

  • 麻酔薬の世界市場:種類別
    • 一般麻酔薬
    • 脊椎麻酔
    • 抹消神経ブロック(PNB)
    • サドルブロック麻酔
    • 射角筋間ブロック麻酔
    • 経静脈局所麻酔法
  • 麻酔薬の世界市場:麻酔方法別
    • 吸入麻酔
    • 静脈麻酔
  • 麻酔薬の世界市場:製品別
    • プロポフォール
    • セボフルラン
    • デスフルラン
    • レミフェンタニル
    • ミゾタラム
    • デクスメデトミジン
    • その他

第5章 競合情勢

  • 主要戦略
    • 合併・買収
    • ジョイントベンチャー
    • 新製品の投入
    • パートナーシップ
  • 上位10社の分析

第6章 地域区分

  • 意思支援データベース・推計手法
  • 市場セグメントの比較分析
  • 市場機会のマトリクス
  • 麻酔薬の世界市場:地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第7章 企業プロファイル

  • ABBOT LABORATORIES
  • ASTRA ZENECA
  • BAXTER INTERNATIONAL INC
  • BOEHRINGER INGELHEIM
  • エーザイ
  • FRESENIUS SE & CO KGAA
  • HIKMA PHARMACEUTICALS PLC
  • HOSPIRA INC
  • MYLAN NV
  • NOVARTIS
  • PAR PHARMACEUTICALS COMPANIES INC
  • PIRAMAL
  • PFIZER
  • ROCHE
  • SAS INSTITUTE, INC.
目次
Product Code: HPH-7380917

The anesthesia drug market is developing and expanding at a significant pace on the global scenario owing to enhancing utility of the anesthesia drugs in the surgeries and transplants considering the medical sector. The anesthesia drug has made a huge impact in the innovation and growth of the medical sector and mainly in the branches of medical sector which includes surgeries and treatment of chronic diseases such as cardiovascular diseases. The anesthesia drug market is mainly driven by the rising healthcare expenditure in the regions such as North America and Europe.. The rising utility of inhalation which is a route of administration is acting as a key trend in the Anesthesia drug market. The presence of various clinical research labs in North America and Europe working towards the introduction of new anesthesia drugs are also boosting the anesthesia drug market. The lack of medical facilities in the underdeveloped nations and presence of few of experienced medical experts and surgeons are hindering the growth of the market.

The general anesthesia segment of the type segment is anticipated to be the dominating segment during the forecasted period of 2016-2023. The general anesthesia has its utility in various surgeries and treatment of diseases which mainly includes the cardiovascular, obesity and orthopedic surgeries on the global scenario. The product segment of the anesthesia drug market is anticipated to be the fastest growing segment due to the utility of the anesthetic drugs which mainly includes isoflurane, sevoflurane, Propofol, in the medical treatment and surgeries occurring in both the male and female body. These drugs also have their pivotal utility in the child delivery as they impact the female body by making it numb so that she doesn't feel the pain during or after surgery.

Geographically, the anesthesia drug market is divided mainly into regions such as North America, Europe, Asia-pacific and rest of the world. The Asia-pacific region is anticipated to witness the fastest growth in the forthcoming years owing to the rising number of hospitals & diagnostic centers and, framework of healthcare reforms and policies (mainly by the countries such as China and India) to expand access considering health care facilities for the common public. The enhancing demand of Propofol is mainly in the market of United States and Canada. The enhancing focus of large number of playershaving presence in the anesthesia drug market, works towards finding the new ways of administration, which includes topical and oral,are also supporting the growth of the market in the North American region. The medical experts' union states that the rising demand considering child delivery will directly impact the growth of anesthesia drug market. The European region is also expected to have growth opportunities in the anesthesia drug market due to supportive norms and policies considering the healthcare mainly in the United Kingdom and Germany, and presence of many clinical research labs working towards the innovation and development of new anesthetic drugs in the European market.

The Major organizations operating in the anesthesia drug market includes Piramal, Novartis, Mylan NV, Hospira Inc, ABBOT laboratories and Baxter International PLC.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. GLOBAL ANESTHESIA DRUG MARKET: EVOLUTION & TRANSITION
  • 2.2. MARKET DEFINITION & SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. TOTAL MARKET ANALYSIS
    • 2.4.1. TOP 5 FINDINGS
    • 2.4.2. TOP 5 OPPORTUNITY MARKETS
    • 2.4.3. TOP 5 COMPANIES
    • 2.4.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.5. ESTIMATION ANALYSIS
  • 2.6. STRATEGIC ANALYSIS
    • 2.6.1. INVESTMENT VS. ADOPTION MODEL
    • 2.6.2. 360 DEGREE INDUSTRY ANALYSIS
    • 2.6.3. PORTERS 5 FORCE MODEL
    • 2.6.4. SEE-SAW ANALYSIS
    • 2.6.5. GAP ANALYSIS
    • 2.6.6. PATENT ANALYSIS
    • 2.6.7. PRICING ANALYSIS
    • 2.6.8. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.7. COMPETITIVE ANALYSIS
    • 2.7.1. KEY STRATEGIES & ANALYSIS
    • 2.7.2. MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS
  • 2.8. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.8.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.8.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.8.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. RISING NUMBER OF SURGERIES
    • 3.1.2. EVOLUTION OF NEW SEDATIVE 7 ANESTHETIC DRUGS
    • 3.1.3. DECREASE IN THE PRICE OF NEWLY INVENTED DRUGS
    • 3.1.4. REDUCTION IN THE RECOVERY TIME SUBSEQUENTLY SURGERY
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. SIDE EFFECTS OF ANESTHESIA DRUGS
    • 3.2.2. AVAILABILITY OF SKILLED ANESTHETICS EXPERTS
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. RISING PRIVATE & PUBLIC HEALTH INSURERS
    • 3.3.2. AVAILABILITY IN GENERIC FORM & LOW COST PRODUCTS
  • 3.4. MARKET CHALLENGES
    • 3.4.1. IMPACT ON NARROW RANGE OF AILMENTS

4. MARKET SEGMENTATION

  • 4.1. GLOBAL ANESTHESIA DRUG MARKET BY TYPE
    • 4.1.1. MARKET DEFINITION AND SCOPE
    • 4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.1.4. OPPORTUNITY MATRIX
    • 4.1.5. MARKET SEGMENTATION
      • 4.1.5.1. GLOBAL GENERAL ANESTHESIA MARKET
        • 4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.1.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.1.4. KEY CONCLUSIONS
      • 4.1.5.2. GLOBAL SPINAL ANESTHESIA MARKET
        • 4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.2.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.2.4. KEY CONCLUSIONS
      • 4.1.5.3. GLOBAL PERIPHERAL NERVE BLOCK MARKET
        • 4.1.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.3.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.3.4. KEY CONCLUSIONS
      • 4.1.5.4. GLOBAL SADDLE BLOCK ANESTHESIA MARKET
        • 4.1.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.4.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.4.4. KEY CONCLUSIONS
      • 4.1.5.5. GLOBAL INTERSCALENE BLOCK MARKET
        • 4.1.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.5.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.5.4. KEY CONCLUSIONS
      • 4.1.5.6. GLOBAL IV REGIONAL ANESTHESIA MARKET
        • 4.1.5.6.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.5.6.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.6.4. KEY CONCLUSIONS
  • 4.2. GLOBAL ANESTHESIA DRUG MARKET BY ROUTES OF ADMINISTRATION
    • 4.2.1. MARKET DEFINITION AND SCOPE
    • 4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.2.4. OPPORTUNITY MATRIX
    • 4.2.5. MARKET SEGMENTATION
      • 4.2.5.1. GLOBAL INJECTION MARKET
        • 4.2.5.1.1. APPLICATION
        • 4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.1.4. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.1.5. KEY CONCLUSIONS
      • 4.2.5.2. GLOBAL INHALATION MARKET
        • 4.2.5.2.1. APPLICATION
        • 4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.2.4. KEY PLAYERS & KEY PRODUCTS
  • 4.3. GLOBAL ANESTHESIA DRUG MARKET BY PRODUCT
    • 4.3.1. MARKET DEFINITION AND SCOPE
    • 4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.3.4. OPPORTUNITY MATRIX
    • 4.3.5. MARKET SEGMENTATION
      • 4.3.5.1. GLOBAL PROPOFOL MARKET
        • 4.3.5.1.1. APPLICATION
        • 4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.1.4. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.1.5. KEY CONCLUSIONS
      • 4.3.5.2. GLOBAL SEVOFLURANE MARKET
        • 4.3.5.2.1. APPLICATION
        • 4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.2.4. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.2.5. KEY CONCLUSIONS
      • 4.3.5.3. GLOBAL DESFLURANE MARKET
        • 4.3.5.3.1. APPLICATION
        • 4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.3.4. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.3.5. KEY CONCLUSIONS
      • 4.3.5.4. GLOBAL REMIFENTANIL MARKET
        • 4.3.5.4.1. APPLICATION
        • 4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.4.4. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.4.5. KEY CONCLUSIONS
      • 4.3.5.5. GLOBAL MIDAZOLAM MARKET
        • 4.3.5.5.1. APPLICATION
        • 4.3.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.5.4. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.5.5. KEY CONCLUSIONS
      • 4.3.5.6. GLOBAL DEXMEDETOMIDINE MARKET
        • 4.3.5.6.1. APPLICATION
        • 4.3.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.6.4. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.6.5. KEY CONCLUSIONS
      • 4.3.5.7. GLOBAL OTHERS MARKET
        • 4.3.5.7.1. APPLICATION
        • 4.3.5.7.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.7.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.7.4. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.7.5. KEY CONCLUSIONS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
    • 5.1.1. LIST OF MERGER & ACQUISITION
    • 5.1.2. LIST OF JOINT VENTURE
    • 5.1.3. LIST OF PRODUCT LAUNCHES
    • 5.1.4. LIST OF PARTNERSHIP
  • 5.2. TOP 10 COMPANY ANALYSIS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.3. OPPORTUNITY MATRIX
  • 6.4. GLOBAL ANESTHESIA DRUG MARKET BY REGION
    • 6.4.1. NORTH AMERICA
      • 6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.1.2. TOP COUNTRY ANALYSIS
        • 6.4.1.2.1. U.S.
          • 6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.1.2.1.3. KEY CONCLUSIONS
        • 6.4.1.2.2. CANADA
          • 6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.1.2.2.3. KEY CONCLUSIONS
    • 6.4.2. EUROPE
      • 6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.2.2. TOP COUNTRY ANALYSIS
        • 6.4.2.2.1. UK
          • 6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.1.3. KEY CONCLUSIONS
        • 6.4.2.2.2. FRANCE
          • 6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.2.3. KEY CONCLUSIONS
        • 6.4.2.2.3. GERMANY
          • 6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.3.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.3.3. KEY CONCLUSIONS
        • 6.4.2.2.4. RUSSIA
          • 6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.4.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.4.3. KEY CONCLUSIONS
        • 6.4.2.2.5. REST OF EUROPE
          • 6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.5.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.5.3. KEY CONCLUSIONS
    • 6.4.3. ASIA PACIFIC
      • 6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.3.2. TOP COUNTRY ANALYSIS
        • 6.4.3.2.1. CHINA
          • 6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.1.3. KEY CONCLUSIONS
        • 6.4.3.2.2. INDIA
          • 6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.2.3. KEY CONCLUSIONS
        • 6.4.3.2.3. JAPAN
          • 6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.3.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.3.3. KEY CONCLUSIONS
        • 6.4.3.2.4. AUSTRALIA
          • 6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.4.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.4.3. KEY CONCLUSIONS
        • 6.4.3.2.5. REST OF ASIA PACIFIC
          • 6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.5.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.5.3. KEY CONCLUSIONS
    • 6.4.4. ROW
      • 6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.4.2. TOP COUNTRY ANALYSIS
        • 6.4.4.2.1. LATIN AMERICA
          • 6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.4.2.1.3. KEY CONCLUSIONS
        • 6.4.4.2.2. MIDDLE EAST & AFRICA
          • 6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.4.2.2.3. KEY CONCLUSIONS

7. COMPANY PROFILES

  • 7.1. ABBOT LABORATORIES
    • 7.1.1. OVERVIEW
    • 7.1.2. PRODUCT PORTFOLIO
    • 7.1.3. STRATEGIC INITIATIVES
    • 7.1.4. SCOT ANALYSIS
    • 7.1.5. STRATEGIC ANALYSIS
  • 7.2. ASTRA ZENECA
    • 7.2.1. OVERVIEW
    • 7.2.2. PRODUCT PORTFOLIO
    • 7.2.3. STRATEGIC INITIATIVES
    • 7.2.4. SCOT ANALYSIS
    • 7.2.5. STRATEGIC ANALYSIS
  • 7.3. BAXTER INTERNATIONAL INC
    • 7.3.1. OVERVIEW
    • 7.3.2. PRODUCT PORTFOLIO
    • 7.3.3. STRATEGIC INITIATIVES
    • 7.3.4. SCOT ANALYSIS
    • 7.3.5. STRATEGIC ANALYSIS
  • 7.4. BOEHRINGER INGELHEIM
    • 7.4.1. OVERVIEW
    • 7.4.2. PRODUCT PORTFOLIO
    • 7.4.3. STRATEGIC INITIATIVES
    • 7.4.4. SCOT ANALYSIS
    • 7.4.5. STRATEGIC ANALYSIS
  • 7.5. EISAI CO LTD
    • 7.5.1. OVERVIEW
    • 7.5.2. PRODUCT PORTFOLIO
    • 7.5.3. STRATEGIC INITIATIVES
    • 7.5.4. SCOT ANALYSIS
    • 7.5.5. STRATEGIC ANALYSIS
  • 7.6. FRESENIUS SE & CO KGAA
    • 7.6.1. OVERVIEW
    • 7.6.2. PRODUCT PORTFOLIO
    • 7.6.3. STRATEGIC INITIATIVES
    • 7.6.4. SCOT ANALYSIS
    • 7.6.5. STRATEGIC ANALYSIS
  • 7.7. HIKMA PHARMACEUTICALS PLC
    • 7.7.1. OVERVIEW
    • 7.7.2. PRODUCT PORTFOLIO
    • 7.7.3. STRATEGIC INITIATIVES
    • 7.7.4. SCOT ANALYSIS
    • 7.7.5. STRATEGIC ANALYSIS
  • 7.8. HOSPIRA INC
    • 7.8.1. OVERVIEW
    • 7.8.2. PRODUCT PORTFOLIO
    • 7.8.3. STRATEGIC INITIATIVES
    • 7.8.4. SCOT ANALYSIS
    • 7.8.5. STRATEGIC ANALYSIS
  • 7.9. MYLAN NV
    • 7.9.1. OVERVIEW
    • 7.9.2. PRODUCT PORTFOLIO
    • 7.9.3. STRATEGIC INITIATIVES
    • 7.9.4. SCOT ANALYSIS
    • 7.9.5. STRATEGIC ANALYSIS
  • 7.10. NOVARTIS
    • 7.10.1. OVERVIEW
    • 7.10.2. PRODUCT PORTFOLIO
    • 7.10.3. STRATEGIC INITIATIVES
    • 7.10.4. SCOT ANALYSIS
    • 7.10.5. STRATEGIC ANALYSIS
  • 7.11. PAR PHARMACEUTICALS COMPANIES INC
    • 7.11.1. OVERVIEW
    • 7.11.2. PRODUCT PORTFOLIO
    • 7.11.3. STRATEGIC INITIATIVES
    • 7.11.4. SCOT ANALYSIS
    • 7.11.5. STRATEGIC ANALYSIS
  • 7.12. PIRAMAL
    • 7.12.1. OVERVIEW
    • 7.12.2. PRODUCT PORTFOLIO
    • 7.12.3. STRATEGIC INITIATIVES
    • 7.12.4. SCOT ANALYSIS
    • 7.12.5. STRATEGIC ANALYSIS
  • 7.13. PFIZER
    • 7.13.1. OVERVIEW
    • 7.13.2. PRODUCT PORTFOLIO
    • 7.13.3. STRATEGIC INITIATIVES
    • 7.13.4. SCOT ANALYSIS
    • 7.13.5. STRATEGIC ANALYSIS
  • 7.14. ROCHE
    • 7.14.1. OVERVIEW
    • 7.14.2. PRODUCT PORTFOLIO
    • 7.14.3. STRATEGIC INITIATIVES
    • 7.14.4. SCOT ANALYSIS
    • 7.14.5. STRATEGIC ANALYSIS

7.14.6.

  • 7.15. SAS INSTITUTE, INC.
    • 7.15.1. OVERVIEW
    • 7.15.2. PRODUCT PORTFOLIO
    • 7.15.3. STRATEGIC INITIATIVES
    • 7.15.4. SCOT ANALYSIS
    • 7.15.5. STRATEGIC ANALYSIS

LIST OF TABLES

  • TABLE 1. GLOBAL ANESTHESIA DRUG MARKET BY TYPE 2014-2023 ($ MILLION)
  • TABLE 2. GLOBAL GENERAAL ANESTHESIA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 3. GLOBAL SPINAL ANESTHESIA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 4. GLOBAL PERIPHERAL NERVE BLOCK MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 5. GLOBAL SADDLE BLOCK ANESTHESIA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 6. GLOBAL INTERSCALENE BLOCK ANESTHESIA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 7. GLOBAL IV REGIONAL ANESTHESIA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 8. GLOBAL ANESTHESIA DRUG MARKET BY ROUTES OF ADMINISTRATION 2014-2023 ($ MILLION)
  • TABLE 9. GLOBAL INJECTION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 10. GLOBAL INHALATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 11. GLOBAL ANESTHESIA DRUG MARKET BY PRODUCT 2014-2023 ($ MILLION)
  • TABLE 12. GLOBAL ANESTHESIA DRUG MARKET IN PROPOFOL BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 13. GLOBAL ANESTHESIA DRUG MARKET SEVOFLURANE BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 14. GLOBAL DESFLURANE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 15. GLOBAL REMIFENTANIL MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 16. GLOBAL MIDAZOLAM MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 17. GLOBAL DEXMEDETOMIDINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 18. GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 19. GLOBAL AUTOMOTIVE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • TABLE 20. NORTH AMERICA ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • TABLE 21. EUROPE ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • TABLE 22. ASIA PACIFIC ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • TABLE 23. REST OF THE WORLD ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANESTHESIA DRUG MARKET BY GENERAL ANESTHESIA 2014-2023 ($ MILLION)
  • FIGURE 2. GLOBAL ANESTHESIA DRUG MARKET BY SPINAL ANESTHESIA 2014-2023 ($ MILLION)
  • FIGURE 3. GLOBAL ANESTHESIA DRUG MARKET BY PERIPHERAL NERVE BLOCK 2014-2023 ($ MILLION)
  • FIGURE 4. GLOBAL ANESTHESIA DRUG MARKET BY SADDLE BLOCK ANESTHESIA 2014-2023 ($ MILLION)
  • FIGURE 5. GLOBAL ANESTHESIA DRUG MARKET BY INTERSCALENE BLOCK 2014-2023 ($ MILLION)
  • FIGURE 6. GLOBAL ANESTHESIA DRUG MARKET BY IV REGIONAL ANESTHESIA 2014-2023 ($ MILLION)
  • FIGURE 7. GLOBAL ANESTHESIA DRUG MARKET BY INJECTION 2014-2023 ($ MILLION)
  • FIGURE 8. GLOBAL ANESTHESIA DRUG MARKET BY INHALATION 2014-2023 ($ MILLION)
  • FIGURE 9. GLOBAL ANESTHESIA DRUG MARKET BY PROPOFOL 2014-2023 ($ MILLION)
  • FIGURE 10. GLOBAL ANESTHESIA DRUG MARKET BY SEVOFLURANE 2014-2023 ($ MILLION)
  • FIGURE 11. GLOBAL ANESTHESIA DRUG MARKET BY DESFLURANE 2014-2023 ($ MILLION)
  • FIGURE 12. GLOBAL ANESTHESIA DRUG MARKET BY REMIFANTANIL 2014-2023 ($ MILLION)
  • FIGURE 13. GLOBAL ANESTHESIA DRUG MARKET BY MIDAZOLAM 2014-2023 ($ MILLION)
  • FIGURE 14. GLOBAL ANESTHESIA DRUG MARKET BY DEXMEDETOMIDINE 2014-2023 ($ MILLION)
  • FIGURE 15. GLOBAL ANESTHESIA DRUG MARKET BY OTHERS 2014-2023 ($ MILLION)
  • FIGURE 16. UNITED STATES (U.S.) ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 17. CANADA ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 18. UNITED KINGDOM (UK) ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 19. FRANCE ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 20. GERMANY ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 21. RUSSIA ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 22. ROE ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 23. INDIA ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 24. CHINA ANESTHESIA DRUG MARKET MT 2014-2023 ($ MILLION)
  • FIGURE 25. JAPAN ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 26. AUSTRALIA ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 27. ROAPAC ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 28. LATIN AMERICA ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)
  • FIGURE 29. MENA ANESTHESIA DRUG MARKET 2014-2023 ($ MILLION)